Health
Anti-cancer drug’s mode of operation deciphered – EurekAlert
Freiburg researchers show how the membrane protein CD20 keeps the immune system’s antibody-producing cells in check.
IMAGE: Freiburg researchers investigate how the membrane protein CD20 organizes the nanostructures on the B cell membrane.
view more
Credit: Illustration: Julia Jullesova
Rituximab, an anti-cancer drug targeting the membrane protein CD20, was the first approved therapeutic antibody against B tumor cells. Immunologists at the University of Freiburg have now solved a mystery about how it works. A team headed by Professor Dr. Michael Reth used cell cultures, healthy cells, and cells from cancer patients…
Continue Reading